Summary
This project aims to elucidate the mechanisms by which cancer persister cells survive targeted therapy and to identify druggable targets to eliminate them, specifically in KRAS-mutant non-small cell lung cancer.
Elucidate the landscape of druggable targets for eliminating cancer persister cells
US · IL
NIH
grant
awarded
#nih-1R01CA300245-01
What they want
The work involves illuminating signals that promote persistence in physiopathological contexts, identifying and validating targets that inhibit persistence, and establishing a persister knowledge base with AI-enabled tools to continuously generate target hypotheses. The ultimate goal is to enable rational design of combination treatment strategies that limit opportunities for resistance to evolve with KRAS G12C drug-treated NSCLC.
Deliverables
- Elucidation of mechanisms of persister rewiring
- Pinpointed druggable targets to eradicate persistence
- Illumination of signals that promote persistence in physiopathological contexts
- Identified and validated targets that inhibit persistence
- A persister knowledge base
- AI-enabled tools to continuously generate target hypotheses
- Preclinically validated drug targets
Technical requirements
- AI-enabled tools
Market context
inferred from NAICSProfessional, Scientific & Technical Services
NAICS 541714
- US market size
- $2.0T
- Typical award
- $25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP
Sector-level estimate — full code lookup not yet in catalog.
